HLB Life Science Co., Ltd. (KOSDAQ:067630)
South Korea · Delayed Price · Currency is KRW 3,105.00
+130.00 (4.37%)
Jun 9, 2026, 3:30 PM KST
HLB Life Science Cash Flow Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | -50,452 | -99,794 | 6,138 | -5,983 | -54,277 | -49,152 |
Depreciation & Amortization | 6,518 | 5,247 | 5,901 | 7,696 | 5,223 | 2,484 |
Loss (Gain) From Sale of Assets | 3,189 | 3,130 | -23.84 | 234.83 | -3,157 | -593.47 |
Asset Writedown & Restructuring Costs | 6,073 | 6,073 | 24,162 | 37,553 | 14,802 | 13,786 |
Loss (Gain) From Sale of Investments | 11,660 | 63,329 | -61,670 | -81,336 | 20,548 | 24,871 |
Loss (Gain) on Equity Investments | -2,501 | -2,406 | -1,354 | 2,607 | -2,602 | -3,576 |
Stock-Based Compensation | 72.76 | 55.35 | - | - | - | - |
Provision & Write-off of Bad Debts | -421.7 | -166.33 | -3,233 | -91.76 | -173.85 | -292.94 |
Other Operating Activities | 7,740 | 7,633 | 2,923 | 23,543 | 3,135 | -2,213 |
Change in Accounts Receivable | -6,805 | -4,541 | -6,780 | 4,031 | 10,149 | -1,552 |
Change in Inventory | -1,595 | -3,460 | -421.43 | 5,300 | -2,515 | 221.34 |
Change in Accounts Payable | -1,336 | -479.08 | 1,508 | -4,072 | -5,610 | 4,730 |
Change in Other Net Operating Assets | 4,364 | 2,447 | 845.87 | 501.09 | -15,265 | -2,798 |
Operating Cash Flow | -23,493 | -22,933 | -32,005 | -10,016 | -29,744 | -14,084 |
Capital Expenditures | -19,536 | -25,582 | -27,296 | -20,618 | -10,676 | -2,421 |
Sale of Property, Plant & Equipment | -692.26 | 314.4 | 98.78 | 6,652 | 832.86 | 3,526 |
Cash Acquisitions | 0 | -3,070 | - | -9,029 | -43,184 | - |
Divestitures | 17,355 | 17,355 | - | - | - | - |
Sale (Purchase) of Intangibles | -436.34 | -360.24 | -170.68 | 326.9 | -1,044 | -46 |
Investment in Securities | -34,173 | -24,437 | -8,914 | 13,786 | -25,597 | 5,712 |
Other Investing Activities | 1,147 | 1,147 | -1,500 | 0 | 6,846 | 1,920 |
Investing Cash Flow | -36,336 | -34,633 | -37,781 | -8,883 | -72,643 | 8,822 |
Short-Term Debt Issued | - | 18,940 | 48,000 | 7,710 | 7,400 | 1,000 |
Long-Term Debt Issued | - | 18,829 | 77,570 | 10,870 | 98,760 | - |
Total Debt Issued | 80,769 | 37,769 | 125,570 | 18,580 | 106,160 | 1,000 |
Short-Term Debt Repaid | - | -5,147 | -49,307 | -5,000 | -4,000 | -1,000 |
Long-Term Debt Repaid | - | -14,356 | -77,296 | -8,256 | -1,322 | -642.24 |
Total Debt Repaid | -59,527 | -19,503 | -126,603 | -13,256 | -5,322 | -1,642 |
Net Debt Issued (Repaid) | 21,242 | 18,266 | -1,033 | 5,324 | 100,837 | -642.24 |
Issuance of Common Stock | 57.82 | 108.61 | 106,977 | - | 1,000 | 129.25 |
Repurchase of Common Stock | - | - | - | -679.97 | - | - |
Other Financing Activities | 28.38 | -115.31 | -200.49 | 142.28 | 259.37 | -128.1 |
Financing Cash Flow | 21,329 | 18,259 | 105,744 | 4,786 | 102,096 | -641.09 |
Foreign Exchange Rate Adjustments | -83.51 | -127.1 | -0.52 | -97.04 | 15.56 | 0.05 |
Miscellaneous Cash Flow Adjustments | 0 | - | - | -0 | - | - |
Net Cash Flow | -38,584 | -39,434 | 35,956 | -14,210 | -275.23 | -5,903 |
Free Cash Flow | -43,030 | -48,515 | -59,301 | -30,634 | -40,420 | -16,505 |
Free Cash Flow Margin | -83.53% | -106.04% | -180.96% | -31.26% | -40.59% | -30.85% |
Free Cash Flow Per Share | -352.86 | -398.03 | -531.38 | -300.99 | -400.32 | -166.14 |
Cash Interest Paid | 4,956 | 3,596 | 2,919 | 2,728 | 674.73 | 250.99 |
Cash Income Tax Paid | - | -52.91 | 7,785 | -703.65 | 1,140 | -569.35 |
Levered Free Cash Flow | -20,645 | -42,441 | -60,323 | -29,493 | -33,595 | -10,410 |
Unlevered Free Cash Flow | -12,980 | -35,101 | -49,824 | -15,961 | -27,426 | -9,625 |
Change in Working Capital | -5,373 | -6,033 | -4,848 | 5,761 | -13,241 | 601.65 |